ReviewActa pharmaceutica Sinica. B2022
Non-apoptotic cell death-based cancer therapy: Molecular mechanism, pharmacological modulators, and nanomedicine.
Review in Acta pharmaceutica Sinica. B, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 117 citations in OpenAlex.
- A Ferrous-Supply-Regenerating Lipid Nanoparticle Integrating RNAi Induces Ferroptosis for Cancer Therapy.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- UCHL1-mediated deubiquitination of PARK7 suppresses ferroptosis and enhances tumor progression in triple-negative breast cancer.Molecular and cellular biochemistry · 2026Article
- Computer-Aided Discovery of EGFR G-Quadruplex Targeting Phenanthroimidazole Derivatives Inducing Concurrent Multi-Organelle Damage in Glioblastoma.Antioxidants (Basel, Switzerland) · 2026Article
- PCBP2 mediates MTUS1 degradation through 3'-UTR binding to restrict pyroptosis and augment malignant progression in esophageal squamous cell carcinoma.Esophagus : official journal of the Japan Esophageal Society · 2026Article
- Metal-organic framework nanoparticles induced non-apoptotic cell death: Construction, mechanisms, and cancer therapy.Materials today. Bio · 2026Review
- Novel Silver(I) and Gold(I) N-Heterocyclic Carbene Complexes Induce ROS-Dependent Autophagic Cell Death in Human Hepatoma Cell Line HepG2.Chemical biology & drug design · 2026Article
- Mitocurcumin induces ROS-/JNK-mediated paraptosis to overcome chemoresistance in non-small cell lung cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Review
- Harnessing photodynamic therapy for programmed cell death: the central role and contributions of metal complexes as next generation photosensitizers.RSC medicinal chemistry · 2025Review
- Deactivation of CK1α enhances the anti-cancer effects of salinomycin in colorectal cancer HCT116 cells.Biochemistry and biophysics reports · 2025Article
- Advancing the understanding of the role of apoptosis in lung cancer immunotherapy: Global research trends, key themes, and emerging frontiers.Human vaccines & immunotherapeutics · 2025Article
- PV-10 Triggers Immunogenic Cell Death in Head and Neck Squamous Cell Carcinoma via Endoplasmic Reticulum Stress and Apoptosis.Molecular cancer therapeutics · 2025Article
- Transformative potential of plant-based nanoparticles in cancer diagnosis and treatment: bridging traditional medicine and modern therapy.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- From mechanism to application: programmed cell death pathways in nanomedicine-driven cancer therapies.Bioactive materials · 2025Review
- Light-activated multimodal nanoplatform for enhanced synergistic therapy of breast cancer.Scientific reports · 2025Article
- Mechanism of Brucea javanica against multiple myeloma via TNF-NF-κB signaling.Scientific reports · 2025Article
- Inherently anti-metastatic peptide hydrogels for sonodynamic-amplified ferroptosis in cancer therapy.Materials today. Bio · 2025Article
- Cell-Specific Vulnerability of Human Glioblastoma and Astrocytoma Cells to Mephedrone-An In Vitro Study.Molecules (Basel, Switzerland) · 2025Article
- Stilbene Glycosides inPlants (Basel, Switzerland) · 2025Article
- Biotransformation and biological fate of magnetic iron oxide nanoparticles for biomedical research and clinical applications.Nanoscale advances · 2025Review
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As an emerging cancer therapeutic target, non-apoptotic cell death such as ferroptosis, necroptosis and pyroptosis, etc., has revealed significant potential in cancer treatment for bypassing apoptosis to enhance the undermined therapeutic efficacy triggered by apoptosis resistance. A variety of anticancer drugs, synthesized compounds and natural products have been proven recently to induce non-apoptotic cell death and exhibit excellent anti-tumor effects. Moreover, the convergence of nanotechnology with functional materials and biomedicine science has provided tremendous opportunities to construct non-apoptotic cell death-based nanomedicine for innovative cancer therapy. Nanocarriers are not only employed in targeted delivery of non-apoptotic inducers, but also used as therapeutic components to induce non-apoptotic cell death to achieve efficient tumor treatment. This review first introduces the main characteristics, the mechanism and various pharmacological modulators of different non-apoptotic cell death forms, including ferroptosis, necroptosis, pyroptosis, autophagy, paraptosis, lysosomal-dependent cell death, and oncosis. Second, we comprehensively review the latest progresses of nanomedicine that induces various forms of non-apoptotic cell death and focus on the nanomedicine targeting different pathways and components. Furthermore, the combination therapies of non-apoptotic cell death with photothermal therapy, photodynamic therapy, immunotherapy and other modalities are summarized. Finally, the challenges and future perspectives in this regard are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.